

17 November 2025

## Company Update – New A\$11m Financing Facility Secured to Complete Strategic Acquisition

### Highlights:

- **A\$11m Financing Facility Secured with US-based venture fund C/M Capital, to Complete Strategic Acquisition and finance future sales focused growth strategies**
- **C/M Capital continues ongoing financial backing of the development and North and South American target markets for Argent’s leading products, CannEpil and CimetrA**
- **Financing facility enables Argent to complete acquisition of AusCann Group assets**
- **Acquisition includes Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, access to fully operational EU-GMP grade cannabinoid manufacturing facility in Europe, and large German pharma distribution network**
- **Board and management changes to lead the new company strategy**
- **Argent will now fast-track plans to pursue dual listing on one of the main U.S. stock exchange**

**Argent BioPharma Ltd. (ASX: RGT)** is pleased to announce that it has secured funding from two investment funds managed by US-based C/M Capital Partners, LP and has entered into a new convertible securities financing agreement (**Financing Agreement**) with C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC, both United States-based institutional funds to provide the Company with a substantial funding facility of up to a total of A\$11,000,000. This will include an immediate \$3,000,000 drawdown for working capital and to complete the AusCann assets acquisition.

C/M Capital have been a long term financier and key supporter of Argent since 2020, and are very pleased to continue their financial and advisory support to the Company. C/M Capital have deep rooted experience and expertise in investing in biotech and biopharma technology and development companies in the USA and on the ASX, including funding companies like Dimerix Limited (ASX: DXB)

### **New \$11m Funding Secured with C/M Capital**

This funding package allows the Company to advance the acquisition of the AusCann Group Holdings Limited (AusCann) assets valued at US\$15 million<sup>1</sup>. The transaction provides access to the Neuvis oral delivery technology, the CannPal clinical and IP portfolio, and a 19.99% position in ECC Pharm Limited and its German distribution platform, providing the Company immediate access to an established EU GMP production and distribution pathway that is already active and aligned with the recent approvals and listings of CannEpil and Cognicann in Germany. Together, these elements create a strong commercial and regulatory base to accelerate market entry and growth across Europe.

With the streamlined operating structure now in place, the financing provides the Company with more than twelve months of operating runway, positioning Argent to enter 2026 as a fully funded and operationally efficient biopharmaceutical company. This financing is not only a capital raise, but a strategic step that positions the Company to integrate the AC8 assets, expand its commercial footprint, and advance toward a national U.S. stock exchange

<sup>1</sup> Refer to ASX Announcement dated 19 August 2025

listing with strengthened momentum. Following the C/M Capital new financing facility and AusCann deal completion, Andrew Chapman will join the Board as Executive Director, Roby Zomer will become the Non-Executive Chairman and Gary Hermon will step down from the Board. Daniel Robinson will continue as an independent Non-Executive Director.

The first tranche of A\$3,000,000 will provide the funding required to complete the AC8 asset acquisition. This tranche will be released upon lodgement of a cleansing statement and will be subject to shareholder approval at the Company's 2025 Annual General Meeting. Following completion, a total of 3,300,000 Convertible Notes, each with a face value of A\$1.00, will be issued to C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund, LLC.

### C/M Capital \$11m Financing Facility

The key terms of the C/M Capital Financing Agreement are set out below:

- Unsecured Convertible Securities facility of up to A\$11,000,000 in total;
- The initial tranche of convertible securities will provide funding of A\$3,000,000 to Argent BioPharma, subject to shareholder approval;
- Subsequent tranches of funding are available up to a value of AUD\$8M within 18 months of execution of the agreement, with access to the additional funding subject to usual conditions and agreement of the parties;
- Face value of 110% of the investment amount;
- The term of each of the Convertible Notes is 18 months from their issue;
- 21,950,952 options to the extent of 75% of the funded amount are also to be issued, however, no commencement shares are to be issued;
- The initial investment amount is to be split between two funds - C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC; and
- Convertible at the lower of A\$0.10 or 90% of the lowest daily VWAP during the preceding 15 Trading Days on which Shares were traded in the ordinary course of business on the ASX immediately prior to delivery of the relevant Conversion Notice; subject to the Conversion Price not being less than A\$0.04.

**Roby Zomer, Managing Director and CEO:** *"We warmly welcome this investment and the entry of highly experienced U.S. market professionals into our shareholder base. Their decision to partner with Argent BioPharma reflects a clear alignment with our strategy and confidence in the milestones ahead, including the completion of the AC8 asset integration and our progression toward a U.S. national market listing.*

*Working alongside a fund and fund manager with deep expertise in the U.S. capital markets brings additional insight and discipline that will support our next phase of growth. This partnership strengthens our operational and financial position, and we look forward to advancing Argent as a fully funded, efficient, and globally focused biopharmaceutical company."*

### Deed of Variation for Convertible Notes

Additionally, the Company has executed a deed of variation whereby an agreement was reached with Mercer Street Global Fund LLC (the prior fund to C/M Capital) to amend, subject to shareholder approval at the Company's 2025 Annual General Meeting, the terms of 450,000 Convertible Notes issued under the 2020 Convertible Note facility (2020 Facility)<sup>2</sup> and 3,410,000 Convertible Notes issued under the 2022 Convertible Note facility (2022 Facility)<sup>3</sup>. Pursuant to the variation, the minimum Conversion Price of the 450,000 Convertible Notes issued under the 2020

<sup>2</sup> Refer to ASX Announcement dated 15 September 2020

<sup>3</sup> Refer to ASX Announcement dated 29 July 2022

Facility will be amended to 92% of the lowest daily VWAP of Shares over 10 trading days prior to conversion, subject to a minimum Conversion Price of A\$0.04, and the Maturity Date extended to 28 November 2026. The minimum conversion price of 3,410,000 Convertible Notes issued under the 2022 Facility will be amended to, in respect of 1,320,000 Convertible Notes 92% of the lowest daily VWAP over 10 trading days prior to conversion, in respect of 2,090,000 Convertible Notes 90% of the lowest daily VWAP over 10 trading days prior to conversion, subject to a minimum Conversion Price of A\$0.04. The Maturity Dates will also be amended to 28 November 2026 for all Convertible Securities issued on or before 1 November 2022, and 18 months from issue for any issued thereafter.

-ENDS-

Authorised for release by the board of directors, for further information, please contact:

**Argent BioPharma**

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**

Rowan Harland

Company Secretary

+61 8 6555 2950

[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma Ltd. (ASX: RGT)** is a clinical-stage biopharmaceutical company developing nano-engineered medicines that restore balance between the nervous and immune systems. Its lead candidates, CannEpil<sup>®</sup> and CimetrA<sup>®</sup>, target drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, respectively. The Company's proprietary delivery platforms are designed to improve penetration across the blood-brain and alveolar-capillary barriers, enabling differentiated efficacy and supporting composition-of-matter protection. With EU-GMP manufacturing, advancing late-stage clinical programs, and a unified Neuro-Immune Modulatory platform, Argent BioPharma is building a high-impact pipeline with a clear focus on urgent unmet needs in CNS and systemic inflammation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma